For patients with hormone receptor–positive (HR+) advanced breast cancer who progress after treatment with CDK4/6 inhibitors, should clinicians choose antibody–drug conjugates (ADCs) or a combination of targeted therapy plus endocrine therapy (ET)? At the 2025 Summer Breast Cancer Forum · Northern Salon, the “Debate” session addressed this very question. Professor Ning Xie of Hunan Cancer Hospital and Professor Lingzhi Xu of the Second Affiliated Hospital of Dalian Medical University presented evidence-based arguments for ADCs and for targeted therapy + ET, respectively. In this Oncology Frontier feature, they further elaborate on their viewpoints.

The 16th Yan Zhao Breast Cancer Forum was held in Shijiazhuang from August 27–31, 2025. The event was jointly organized by the Breast Cancer Committee of the Hebei Anti-Cancer Association and multiple specialty committees, co-organized by the Beijing Breast Disease Prevention and Treatment Society, and hosted by the Fourth Hospital of Hebei Medical University and the Hebei Breast Disease Diagnosis and Treatment Center. This year’s forum emphasized standardization and innovation in breast cancer diagnosis and treatment, with highlights including guideline roadshows and robotic surgery. During the meeting, Oncology Frontier interviewed the conference chair, Professor Cuizhi Geng of the Fourth Hospital of Hebei Medical University, who shared insights on the forum highlights, the role of guideline dissemination, strategies for regional treatment homogeneity, and the clinical application and challenges of robot-assisted breast surgery.

From August 27–31, 2025, the 16th Yan Zhao Breast Cancer Forum was held grandly in Shijiazhuang. The event was jointly organized by the Breast Cancer Committee of the Hebei Anti-Cancer Association and several other specialty committees, co-organized by the Beijing Breast Disease Prevention and Treatment Society, and hosted by the Fourth Hospital of Hebei Medical University and the Hebei Breast Disease Diagnosis and Treatment Center. This year’s forum focused on multidisciplinary innovations and cutting-edge concepts in breast cancer management, aiming to advance standardized care and elevate regional treatment standards. At the meeting, Oncology Frontier invited the conference chair, Professor Yunjiang Liu of the Fourth Hospital of Hebei Medical University, for an in-depth interview. He discussed the core principles of oncoplastic surgery (OPS) in breast-conserving surgery, shared clinical experience and outcomes from the multidisciplinary team (MDT) model, and offered forward-looking perspectives on promoting greater uniformity in breast cancer care across the region and nationwide.

Insights from the 2025 Pujiang Urologic Oncology Congress Editor’s Note: The 2025 Pujiang Urologic Oncology Congress was held in Shanghai from August 22–23 under the theme “Precision Breakthroughs · Integrated…

Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a distinct pathological subtype of RCC characterized by a well-defined driver mutation and high malignancy. In recent years, studies have shown that…